Choose tirzepatide if you need mature Phase 3 safety data, a confirmed regulatory pathway, simpler titration, or a comparator with established cardiovascular outcome signals
Because of that uncertainty, the FDA labelling recommends weighing the benefits of breastfeeding alongside the mother's need for Zepbound and any possible effects on the baby
The basic formula Concentration (mg/mL) = Total peptide (mg) divided by Total water volume (mL) For a 10mg vial: 10mg divided by 1mL = 10mg/mL 10mg divided by 2mL = 5mg/mL 10mg divided by 3mL = 3.33mg/mL 10mg divided by 5mL = 2mg/mL Calculating your draw volume Draw volume (mL) = Desired dose (mg) divided by Concentration (mg/mL) Example: You want a 4mg dose from a vial reconstituted at 5mg/mL
They're designed to: Confirm the weight loss and metabolic benefits seen in Phase 2 Identify rare side effects that smaller trials might have missed Demonstrate consistent results across diverse populations (age, sex, ethnicity, comorbidities) Build long-term safety data (cardiovascular outcomes, liver health, kidney function) Provide the evidence package the FDA needs to approve the drug Retatrutide's Phase 2 results were strong enough (up to 24.2% weight loss) that Eli Lilly moved it into a large Phase 3 program
